바로가기메뉴

본문 바로가기 주메뉴 바로가기

logo

  • P-ISSN2233-4203
  • E-ISSN2093-8950

LC-MS/MS Method for Simultaneous Analysis of Growth Hormone-Releasing Peptides and Secretagogues in Human Urine

Mass Spectrometry Letters, (P)2233-4203; (E)2093-8950
2016, v.7 no.3, pp.55-63
https://doi.org/10.5478/MSL.2016.7.3.55
Hophil Min (Korea Institute of Science and Technology)
Boyoung Han (Korea Institute of Science and Technology)
Changmin Sung (Korea Institute of Science and Technology)
Ju-Hyung Park (Korea Institute of Science and Technology)
Kang Mi Lee (Korea Institute of Science and Technology)
Ho Jun Kim (Korea Institute of Science and Technology)
Ki Hun Kim (Korea Institute of Science and Technology)
Junghyun Son (Korea Institute of Science and Technology)
Oh-SeungKwon (Korea Institute of Science and Technology)
Jaeick Lee (Korea Institute of Science and Technology)
  • Downloaded
  • Viewed

Abstract

Growth hormone (GH)-releasing peptides (GHRPs) and GH secretagogues (GHSs) are listed in the World Anti-Doping Agency (WADA) Prohibited List. In the present study, we developed and validated a method for the simultaneous analysis of seven GHRPs (alexamorelin, GHRP-1, -2, -4, -5, -6, and hexarelin) and three GHSs (anamorelin, ibutamoren, and ipamorelin) in human urine. Method validation was performed at minimum required performance levels specified by WADA technical documents (2 ng/mL) for all substances, and the method was validated with regard to selectivity (no interference), linearity (R2 > 0.9986), matrix effects (50.0%-141.2%), recovery (10.4%-100.8%), and intra- (2.8%-16.5%) and inter-day (7.0%-22.6%) precisions. The limits of detection for screening and confirmation were 0.05-0.5 ng/mL and 0.05-1 ng/mL, respectively.

Submission Date
2016-08-11
Revised Date
2016-09-29
Accepted Date
2016-09-29

Reference

1

Saugy, M.. (2006). . Brit J. Sport Med, 40(Suppl 1), i35-.

2

Saugy, M.. (1996). . J. Chromatogr. B, 687, 201-.

3

Baumann, G. P.. (2012). . Endocr. Rev, 33, 155-.

4

Bowers, C. Y.. (1991). . Endocrinology, 128, 2027-.

5

Arvat, E.. (2001). . J. Clin. Endocr. Metab, 86, 1169-.

6

Okano, M.. (2010). . Drug Test Anal, 2, 548-.

7

Garcia, J. M.. (2009). . Growth Horm. Igf. Res, 19, 267-.

8

Svensson, J.. (2003). . Growth Horm Igf. Res, 13, 1-.

9

Thomas, A.. (2011). . Anal. Bioanal. Chem, 401, 507-.

10

Okano, M.. (2010). . Rapid Commun. Mass Spectrom, 24, 2046-.

11

Thomas, A.. (2012). . Anal. Chem, 84, 10252-.

12

Sobolevsky, T.. (2014). . Drug Test Anal, 6, 1087-.

13

Mazzarino, M.. (2015). . Forensic Toxicol, 33, 321-.

14

World Anti-Doping Agency. (2015). Technical Document for minimum required performance levels. https://www.wada-ama.org/en/resources/science-medicine/td2015-mrpl.

Mass Spectrometry Letters